SR Medical Technology Company Limited has alerted shareholders and prospective investors to an anticipated loss attributable to shareholders of approximately HK$68.00 million–HK$73.00 million for the six months ended 30 June 2026, reversing the HK$2.10 million profit recorded in the same period of 2025.

The Board attributes the projected downturn to a sharp escalation in key cost items: • Other operating costs rose by about HK$75.20 million. • Finance costs increased by roughly HK$29.30 million. • Employee benefit expenses expanded by around HK$19.20 million.

These higher expenses outweighed a revenue uplift of approximately HK$52.20 million, which stemmed from the completion of the acquisition of Beijing Chunyu Tianxia Software Co., Ltd. and the full-scale launch of the Culver City project during the review period.

The figures are based on the Group’s preliminary, unaudited management accounts and may be subject to adjustments. SR Medical plans to release its full interim results for the first half of 2026 on 31 August 2026.

The company has advised investors to exercise caution when dealing in its securities. The announcement was approved by Chairman Wei Chunxian and released on 26 August 2026 in Hong Kong.